Magnetofectamine™
The winning combination for optimal transfection efficiency
Ideal to transfect primary and Hard-to-transfect cells, Magnetofectamine™ associates Lipofectamine™ 2000 from Invitrogen™ and OZ Biosciences's CombiMag reagent, increasing the overall efficiency of your transfection while minimizing cytotoxicity.
Lipofectamine™ 2000 is the
leading transfection reagent on the market for simple and effective nucleic acid delivery
CombiMag is a Magnetofection™ based reagent: versatile and improving transfection efficiency without
toxicity.
Magnetofection™ is a creative, simple and highly efficient
method to transfect cells in vitro
and in vivo.
This magnetic assisted
transfection is based on the use of magnetic
nanoparticles associated to the nucleic acid. In this way, the magnetic force allows a rapid concentration of genetic material onto cells and promotes cellular uptake.
|
-
Superior transfection efficiency
-
Enhanced Lipofectamine™ 2000 efficiency
-
Ideal for hard-to-transfect and primary cells
-
Less nucleic acids used - minimized toxicity
-
Serum compatible and applicable to all nucleic acids
-
Simple, ready-to use and rapid
No need to change your standard Lipofectamine™ 2000 protocol
Ask your sample and try Magnetofectamine™ (Lipofectamine™2000 & CombiMag) :
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Results
- Data 1: Superior DNA transfection efficiency in primary cells (Fig.1/2)
- Data 2: Superior transgene expression in a broad spectrum of cell lines (Fig.3)
- Data 3: Magnetofectamine™ exhibits high levels of transfection efficiency
(Fig.4)
- Data 4: Viability and Efficiency - Minimized toxicity (Fig.5)
Product listing
Maximize transfection efficiency
Magnetofectamine™ kit
enhances DNA transfection efficiency and gene expression in a variety of primary cells and cell lines.
In the presence of CombiMag reagent, Lipofectamine™ 2000 delivers plasmid at higher efficiencies, from +30 to 500%.
|
|
Superior DNA transfection efficiency in primary cells
|
|
Fig.1: CombiMag enhanced Lipofectamine™ 2000
transfection efficiency on
primary neurons and primary endothelial cells.
(A) Primary hippocampal and cortical neurons and (B) primary endothelial
cells (HUVEC, PAEC) were transfected with Lipofectamine™ 2000 or Magnetofectamine™ (Lipofectamine™
2000 + CombiMag). Figure (B) is adapted from Basile et al. 2005. Mol Cell Biol. 25:6889-6898.
Fig.2: CombiMag enhanced Lipofectamine™ 2000
transfection efficiency on
primary Chondrocytes, Keratinocytes and Epithelial cells.
Primary cells were transfected with Lipofectamine™ 2000 or Magnetofectamine™.
More results 
|
| Superior transgene expression in cell lines |
|
 
Fig.3: CombiMag enhanced Lipofectamine™ 2000
transfection efficiency on a wide variety of commonly used cell lines as well as on hard-to-transfect cells.
Classical and hard to transfect cell lines were transfected using 0.25 µg and
0.5µg pVectOZ-GFP plasmid respectively complexed with Lipofectamine™ 2000 (grey bars) or with
Lipofectamine™ 2000 and CombiMag
at a DNA/CombiMag ratio of 1:1 (green bars). Results were analysed by cytofluorometry
24 h after transfection.
More results
|
Magnetofectamine™ exhibits high levels of transfection efficiencyUsing Magnetofectamine™, transfection efficiencies exceeding 50% and even 70%
can be achieved into many primary cells, such as HUVEC, Chondrocytes and
human Mesenchymal Stem Cells. |
|
Fig. 4: Magnetofectamine™ efficiently transfects primary cells.
Primary cells were transfected with
Magnetofectamine™ kit in 24-well plate and efficiency
was monitored 48 hours
post-transfection by flow cytometry.
Many other classical and hard-to-transfect cell lines, such as SH-SY5Y, PC-12,
MEF, HMEC-1, C6 are transfected with high levels of transfection efficiency.
|
Minimize cytotoxicity
|
Magnetofectamine™ is performant even with low doses of nucleic acids
resulting in minimized cytotoxicity. The combination of the two technologies, Lipofectamine™ 2000 and CombiMag (MagnetoFection™) enables using smaller amounts of nucleic acid and increasing the overall efficiency of your transfection.
No need to increase the amount of plasmid DNA and reagent to increase transfection efficiency.
|
|
Fig.5: Viability and Efficiency - Minimized toxicity
As the magnetic force drives the gene vector towards the target
cells, Magnetofectamine™
allows the vector dose to get concentrated onto the cell very rapidly
and triggers
delivery via endocytosis. Consequently, high transfection efficiencies can be achieved with
less nucleic acid amount.
More results
|
Lipofectamine™ and Invitrogen™ are Trademarks owned by Life Technologies Corporation.
Lipofectamine™ 2000 is manufactured by Life
Technologies Corporation for OZ Biosciences and provided
under license from Life Technologies Corporation.
| MTX0750 | Magnetofectamine |
Price: Login | | | Contains 750 µL of Lipofectamine™ 2000 + CombiMag 250µL
|
| MTX1000 | Magnetofectamine starting kit |
Price: Login | | | Contains 750 µL of Lipofectamine™ 2000 + CombiMag 250 µL + 1 Magnetic plate (MF10000)
|
|
Products 
Co-transfection protocol